Analysis of Circulating Free DNA May Replace Tumor Biopsy for Detection of Non-Small-Cell Lung Cancer
By LabMedica International staff writers Posted on 10 Mar 2015 |
Image: Erlotinib bound to EGRF at 0.26 nm resolution; surface color indicates hydrophobicity (Photo courtesy of Wikimedia Commons).
A recent paper showed that analysis of circulating free DNA (cfDNA) in blood samples could replace biopsy as a means for detecting patients with advanced non-small-cell lung cancer (NSCLC) that was distinguished by oncogenic epidermal growth factor receptor (EGFR) mutations.
This study was an extension of the 2007-2011 EURTAC (EURopean TArceva vs. Chemotherapy) trial. EURTAC demonstrated the efficacy of erlotinib (Tarceva) compared with standard chemotherapy for the first-line treatment of European patients with advanced NSCLC with oncogenic EGFR mutations (exon 19 deletion or L858R mutations in exon 21) in tumor tissue.
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that specifically targets the EGFR tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. By inhibiting the ATP, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.
In the current study researchers associated with the Spanish Lung Cancer Group examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer as a replacement for tumor biopsies. To this end they used a novel peptide nucleic acid (PNA)–mediated 5´ nuclease real-time polymerase chain reaction (PCR) (TaqMan) assay to examine EGFR mutations in cfDNA isolated from 97 baseline blood samples obtained from patients that had participated in the EURTAC trial.
Results revealed that cfDNA EGFR mutations were detected in 76 of 97 samples (78%) from the patients. Median overall survival was shorter in patients with the L858R mutation in cfDNA than in those with the exon 19 deletion (13.7 versus 30 months). For the 76 patients with EGFR mutations in cfDNA, only erlotinib treatment was an independent predictor of longer disease progression-free survival.
Senior author Dr. Rafael Rosell, professor of medical oncology at the Hospital Germans Trias I Pujol (Badalona, Spain) said, "Testing of tumor tissue remains the recommended method for detecting the presence of oncogenic EGFR mutations; however, the amount of tumor tissue obtained by biopsy is often insufficient, especially in advanced NSCLC, raising the question of whether cfDNA may be used as a surrogate liquid biopsy for the noninvasive assessment of EGFR mutations."
The study was published in the February 26, 2015, online edition of JAMA Oncology.
Related Links:
Hospital Germans Trias i Pujol
This study was an extension of the 2007-2011 EURTAC (EURopean TArceva vs. Chemotherapy) trial. EURTAC demonstrated the efficacy of erlotinib (Tarceva) compared with standard chemotherapy for the first-line treatment of European patients with advanced NSCLC with oncogenic EGFR mutations (exon 19 deletion or L858R mutations in exon 21) in tumor tissue.
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that specifically targets the EGFR tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. By inhibiting the ATP, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.
In the current study researchers associated with the Spanish Lung Cancer Group examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer as a replacement for tumor biopsies. To this end they used a novel peptide nucleic acid (PNA)–mediated 5´ nuclease real-time polymerase chain reaction (PCR) (TaqMan) assay to examine EGFR mutations in cfDNA isolated from 97 baseline blood samples obtained from patients that had participated in the EURTAC trial.
Results revealed that cfDNA EGFR mutations were detected in 76 of 97 samples (78%) from the patients. Median overall survival was shorter in patients with the L858R mutation in cfDNA than in those with the exon 19 deletion (13.7 versus 30 months). For the 76 patients with EGFR mutations in cfDNA, only erlotinib treatment was an independent predictor of longer disease progression-free survival.
Senior author Dr. Rafael Rosell, professor of medical oncology at the Hospital Germans Trias I Pujol (Badalona, Spain) said, "Testing of tumor tissue remains the recommended method for detecting the presence of oncogenic EGFR mutations; however, the amount of tumor tissue obtained by biopsy is often insufficient, especially in advanced NSCLC, raising the question of whether cfDNA may be used as a surrogate liquid biopsy for the noninvasive assessment of EGFR mutations."
The study was published in the February 26, 2015, online edition of JAMA Oncology.
Related Links:
Hospital Germans Trias i Pujol
Latest Pathology News
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments